AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20599163 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes of vessel and lumen at overlapping PES segment
Number of subjects: 184
Study 18586996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment indicators
Number of subjects: 807
Study 18586996 — intervention group
Group type: EXPERIMENTAL
Intervention: General care and psychosocial rehabilitation indicators
Number of subjects: 807
Study 18586996 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderators affecting care conformance
Number of subjects: 807
Study 16076789 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshop, opinion leader influence, and prompts (progress notes, patient letters, or computer chart reminders)
Number of subjects: 92
Study 16076789 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no intervention)
Number of subjects: 92
Study 16076789 — intervention group
Group type: EXPERIMENTAL
Intervention: Three prompt groups (progress notes, patient letters, computer chart reminders)
Number of subjects: 92
Study 11795674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobin (56g/day for 3 days)
Number of subjects: 40
Study 11795674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10445766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methylprednisolone acetate (MPA), 60 mg administered four times at 1-week intervals.
Number of subjects: 25
Study 10445766 — intervention group
Group type: COMPARATOR
Intervention: Epidural methylprednisolone acetate (MPA), 60 mg administered four times at 1-week intervals.
Number of subjects: 25
Study 7829618 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg, orally, daily)
Number of subjects: 14
Study 7829618 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (100 mg, orally, daily)
Number of subjects: 14
Study 2791157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-Young Pill (EYP)
Number of subjects: 154
Study 2791157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropil
Number of subjects: 154
Study 2791157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 214701 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Sitosterol 5.28 g
Number of subjects: 59
Study 214701 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Sitosterol 10.56 g
Number of subjects: 59
Study 214701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 7060328 — intervention group
Group type: EXPERIMENTAL
Intervention: 975‐mg oral doses of aspirin
Number of subjects: 29
Study 7060328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30325888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Disc Arthroplasty (CDA)
Number of subjects: 232
Study 30325888 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Decompression and Fusion (ACDF)
Number of subjects: 232
Study 30049471 — intervention group
Group type: EXPERIMENTAL
Intervention: .04 taper instrumentation
Number of subjects: 78
Study 30049471 — intervention group
Group type: EXPERIMENTAL
Intervention: .06 taper instrumentation
Number of subjects: 78
Study 30049471 — intervention group
Group type: EXPERIMENTAL
Intervention: .08 taper instrumentation
Number of subjects: 78
Study 30049471 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative access cavity (CAC)
Number of subjects: 78
Study 30049471 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional access cavity (TAC)
Number of subjects: 78
Study 30049471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact teeth
Number of subjects: 78
Study 26786399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose estriol vaginal gel 20 μg/g (T1)
Number of subjects: 43
Study 26786399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose estriol vaginal gel 50 μg/g (T2)
Number of subjects: 43
Study 26786399 — intervention group
Group type: COMPARATOR
Intervention: Ovestinon® (estriol 500 μg/0.5 g) (R)
Number of subjects: 43
Study 26786399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 24942563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy
Number of subjects: 70
Study 24942563 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 70
Study 21885390 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-TGI group (n = 61) receiving HFO-TGI sessions with recruitment manoeuvres (RMs) interspersed with lung-protective conventional mechanical ventilation (CMV)
Number of subjects: 125
Study 21885390 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-TGI group (n = 61)
Number of subjects: 125
Study 21885390 — intervention group
Group type: COMPARATOR
Intervention: CMV group (n = 64)
Number of subjects: 125
Study 20126672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone
Number of subjects: 0
Study 20126672 — intervention group
Group type: COMPARATOR
Intervention: Other agents (control)
Number of subjects: 0
Study 17617293 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic azithromycin (2 x 250 mg)
Number of subjects: 14
Study 17617293 — intervention group
Group type: COMPARATOR
Intervention: Branded azithromycin (2 x 250 mg)
Number of subjects: 14
Study 17617293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 14
Study 14693612 — intervention group
Group type: EXPERIMENTAL
Intervention: IV propacetamol 2 g (followed by 1 g)
Number of subjects: 95
Study 14693612 — intervention group
Group type: EXPERIMENTAL
Intervention: IM morphine 10 mg (followed by 5 mg)
Number of subjects: 95
Study 14693612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 14693612 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol vs Morphine
Number of subjects: 95
Study 12161386 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9829638 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV)
Number of subjects: 44
Study 9829638 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir (SQV)
Number of subjects: 44
Study 9829638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (SQV + ZDV)
Number of subjects: 44
Study 9829638 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) or Saquinavir (SQV) monotherapies
Number of subjects: 44
Study 8180293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pantoprazole 40 mg/day
Number of subjects: 0
Study 8180293 — intervention group
Group type: COMPARATOR
Intervention: Oral pantoprazole 60 mg and 80 mg
Number of subjects: 0
Study 8180293 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pantoprazole 40 mg
Number of subjects: 0
Study 2689263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar probe coagulation (BICAP)
Number of subjects: 156
Study 2689263 — intervention group
Group type: COMPARATOR
Intervention: Conventional cold biopsy (CBx)
Number of subjects: 156
Study 2689263 — intervention group
Group type: EXPERIMENTAL
Intervention: BICAP and CBx (combined)
Number of subjects: 156
Study 1106208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml/kg body weight of 95% ethanol
Number of subjects: 10
Study 1106208 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg body weight of 95% ethanol
Number of subjects: 10
Study 1106208 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg delta‐9‐tetrahydrocannabinol (THC)
Number of subjects: 10
Study 1106208 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg delta‐9‐tetrahydrocannabinol (THC)
Number of subjects: 10
Study 1106208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31349677 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music with normal visual perception
Number of subjects: 50
Study 31349677 — intervention group
Group type: COMPARATOR
Intervention: Without music with normal visual perception
Number of subjects: 50
Study 31349677 — intervention group
Group type: EXPERIMENTAL
Intervention: With music with normal visual perception
Number of subjects: 50
Study 31349677 — intervention group
Group type: EXPERIMENTAL
Intervention: With reduced visual perception (ski goggles with occlusion foil)
Number of subjects: 50
Study 28027462 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric force condition (left limb producing 5 times more force than right limb)
Number of subjects: 20
Study 28027462 — intervention group
Group type: COMPARATOR
Intervention: Symmetric force condition
Number of subjects: 20
Study 28027462 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric force condition (general)
Number of subjects: 20
Study 28027462 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric force condition (left limb)
Number of subjects: 20
Study 26022815 — intervention group
Group type: EXPERIMENTAL
Intervention: True air purifiers
Number of subjects: 35
Study 26022815 — intervention group
Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 35
Study 23497457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 20
Study 23497457 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 20
Study 21208586 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (400 mg/d)
Number of subjects: 60
Study 21208586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19282081 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggeration
Number of subjects: 109
Study 19282081 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 109
Study 19282081 — intervention group
Group type: COMPARATOR
Intervention: Natural-watch
Number of subjects: 109
Study 17229769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 120
Study 17229769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15005871 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of ethanol (0.8 g/kg for males and 0.7 g/kg for females)
Number of subjects: 18
Study 15005871 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of ethanol (75% of the high dose)
Number of subjects: 18
Study 15005871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10391561 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/day)
Number of subjects: 29133
Study 10391561 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg/day)
Number of subjects: 29133
Study 8664090 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/codeine combination
Number of subjects: 0
Study 8664090 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol alone
Number of subjects: 0
Study 8664090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1640520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral intravesical electrotherapy (2 courses of 3 weeks each)
Number of subjects: 31
Study 1640520 — intervention group
Group type: COMPARATOR
Intervention: Sham control (electrocatheter placed without activating the stimulator)
Number of subjects: 31
Study 6373097 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 21
Study 6373097 — intervention group
Group type: EXPERIMENTAL
Intervention: atropine (two doses)
Number of subjects: 21
Study 6373097 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine
Number of subjects: 21
Study 6373097 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (control)
Number of subjects: 21
Study 30773797 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPARPROCATH® radiation drape
Number of subjects: 51
Study 29514852 — intervention group
Group type: EXPERIMENTAL
Intervention: Handover education and cognitive aid for the intervention group
Number of subjects: 20
Study 29514852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 28011970 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate
Number of subjects: 100
Study 28011970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23846561 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 1200
Study 23846561 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1200
Study 23706623 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide feedback in a computerized motivational intervention
Number of subjects: 124
Study 23706623 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief motivational intervention without carbon monoxide feedback)
Number of subjects: 124
Study 20834180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hericium erinaceus (HE) cookies for 4 weeks
Number of subjects: 30
Study 20834180 — intervention group
Group type: COMPARATOR
Intervention: Placebo cookies for 4 weeks
Number of subjects: 30
Study 18256990 — intervention group
Group type: EXPERIMENTAL
Intervention: NMO-IgG antibody marker
Number of subjects: 0
Study 18256990 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary in vitro studies
Number of subjects: 0
Study 18256990 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of active immunization and passive transfer animal models
Number of subjects: 0
Study 15766322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 15766322 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study 15766322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 0
Study 15766322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous administration
Number of subjects: 0
Study 15766322 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil products
Number of subjects: 0
Study 15766322 — intervention group
Group type: COMPARATOR
Intervention: All PDE5 inhibitors
Number of subjects: 0
Study 12828588 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiron Hib/AlPO4 vaccine
Number of subjects: 520
Study 12828588 — intervention group
Group type: EXPERIMENTAL
Intervention: VaxemHib (aluminum hydroxide adjuvant) vaccine
Number of subjects: 520
Study 12828588 — intervention group
Group type: EXPERIMENTAL
Intervention: HibTiter (no adjuvant)
Number of subjects: 520
Study 10898671 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus tazobactam (monotherapy)
Number of subjects: 241
Study 10898671 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus tazobactam plus amikacin (combined therapy)
Number of subjects: 241
Study 8925982 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral closed bladder drainage
Number of subjects: 50
Study 8925982 — intervention group
Group type: COMPARATOR
Intervention: Transurethral open bladder drainage
Number of subjects: 50
Study 1505153 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg of liquid ibuprofen
Number of subjects: 39
Study 1505153 — intervention group
Group type: COMPARATOR
Intervention: 10 to 15 mg/kg of liquid acetaminophen (mean dose 11.6 +/- 0.7)
Number of subjects: 39
Study 6512582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vincristine/cyclophosphamide/dactinomycin and vincristine/doxorubicin/dacarbazine at six-week intervals for one year)
Number of subjects: 61
Study 6512582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy, evaluated at six-week intervals)
Number of subjects: 61
Study 30864450 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI categorization based on nutritional status
Number of subjects: 537
Study 30864450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 537
Study 30864450 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) and waist-height index (WHI)
Number of subjects: 537
Study 29950170 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing newborn screening (NGS-NBS)
Number of subjects: 400
Study 26076002 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for chronic musculoskeletal pain
Number of subjects: 250
Study 26076002 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in pain
Number of subjects: 250
Study 26076002 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in depression/anxiety
Number of subjects: 250
Study 24844862 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE score
Number of subjects: 0
Study 22997893 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (0.01 mg/kg before anesthesia and 0.015 mg/kg in CPB)
Number of subjects: 40
Study 22997893 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (placebo)
Number of subjects: 40
Study 20175107 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bereavement negative events
Number of subjects: 0
Study 20175107 — intervention group
Group type: COMPARATOR
Intervention: Control for current externalizing symptoms and recent negative events
Number of subjects: 0
Study 18602375 — intervention group
Group type: EXPERIMENTAL
Intervention: High monetary incentives for correct performance
Number of subjects: 0
Study 18602375 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased task demands
Number of subjects: 0
Study 18602375 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively perceived prospects
Number of subjects: 0
Study 18602375 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased preparatory cognitive control
Number of subjects: 0
Study 18602375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral OFC activity
Number of subjects: 0
Study 15526142 — intervention group
Group type: EXPERIMENTAL
Intervention: NT 201 (4 units)
Number of subjects: 14
Study 15526142 — intervention group
Group type: COMPARATOR
Intervention: BOTOX (4 units)
Number of subjects: 14
Study 14663031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 120 mg tid
Number of subjects: 536
Study 14663031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 240 mg tid
Number of subjects: 536
Study 14663031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 360 mg tid
Number of subjects: 536
Study 14663031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 14663031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (combined treatment groups)
Number of subjects: 536
Study 14663031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (combined treatment groups)
Number of subjects: 536
Study 14663031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (all groups)
Number of subjects: 536
Study 14663031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (all groups)
Number of subjects: 536
Study 14663031 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome measures
Number of subjects: 536
Study 10469959 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade crystalloid cardioplegia
Number of subjects: 62
Study 10469959 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 62
Study 10469959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin administration
Number of subjects: 62
Study 10469959 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical defibrillation
Number of subjects: 62
Study 10469959 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a main stem lesion
Number of subjects: 62
Study 8339631 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC SR 30 mg twice daily
Number of subjects: 264
Study 8339631 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC SR 45 mg twice daily
Number of subjects: 264
Study 8339631 — intervention group
Group type: EXPERIMENTAL
Intervention: NIC SR 60 mg twice daily
Number of subjects: 264
Study 8339631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 8339631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NIC SR groups
Number of subjects: 264
Study 3525264 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.1%
Number of subjects: 152
Study 3525264 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.25%
Number of subjects: 152
Study 3525264 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.5%
Number of subjects: 152
Study 3525264 — intervention group
Group type: COMPARATOR
Intervention: Control lesions
Number of subjects: 152
Study 30289026 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackadder blackcurrant juice (500 mg polyphenols)
Number of subjects: 8
Study 30289026 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 8
Study 29740854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatherhood intervention
Number of subjects: 0
Study 29740854 — intervention group
Group type: COMPARATOR
Intervention: Financial literacy comparison condition
Number of subjects: 0
Study 27323443 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (needling dorsal segment of the Governor Vessel, 7 spots below the spinous processes from T3 to T9)
Number of subjects: 60
Study 27323443 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Omeprazole capsules, 20 mg twice a day for 8 weeks)
Number of subjects: 60
Study 25387891 — intervention group
Group type: EXPERIMENTAL
Intervention: Near focus optical diagnosis
Number of subjects: 558
Study 25387891 — intervention group
Group type: COMPARATOR
Intervention: Standard view optical diagnosis
Number of subjects: 558
Study 24142782 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of fluticasone 125 μg BID
Number of subjects: 457
Study 24142782 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of fluticasone 250 μg BID
Number of subjects: 457
Study 24142782 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone DPI 500 μg BID
Number of subjects: 457
Study 21875351 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GSH supplementation (500 mg twice daily for 4 weeks)
Number of subjects: 40
Study 21875351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19194319 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline replication capacity (RCBL)
Number of subjects: 321
Study 19194319 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 48 CD4 increase (DeltaCD448)
Number of subjects: 321
Study 16957530 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Number of subjects: 0
Study 16957530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0